What is BioCardia?
BioCardia is a clinical-stage regenerative medicine enterprise dedicated to pioneering novel therapeutics for cardiovascular diseases that present substantial unmet medical needs. The company is actively developing proprietary, comprehensive biotherapeutic solutions, notably through its CardiAMP and CardiALLO therapy programs. The clinical outcomes supporting these programs are robust, building upon some of the most rigorous data generated to date within the field. These advancements leverage intramyocardial delivery of marrow-derived cells, positioning BioCardia at the forefront of cardiovascular innovation.
How much funding has BioCardia raised?
BioCardia has raised a total of $8.8M across 1 funding round:
Debt
$4.4M
Debt (2016): $4.4M, investors not publicly disclosed
What's next for BioCardia?
The substantial enterprise-level funding indicates BioCardia is poised for significant scaling and further clinical development. This capital injection is expected to accelerate the advancement of its CardiAMP and CardiALLO programs, potentially leading to pivotal trials and eventual market entry. The strategic nature of the recent investment suggests a strong alignment with partners who recognize the transformative potential of BioCardia's regenerative medicine approach in addressing critical cardiovascular conditions. Future growth will likely focus on expanding clinical trial reach and solidifying its position as a leader in the cardiovascular therapeutics landscape.
See full BioCardia company page
